OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference
15 Octubre 2024 - 1:00AM
Business Wire
Presentation by Professor Laurent
Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of
Nancy) and Bruno Robin (PharmD, Head of OPM Clinical Development)
of safety, pharmacokinetic and pharmacodynamic data from Phase 1 in
healthy volunteers receiving OPM-101 in a moderated poster
session
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63;
Mnemonic: ALOPM), a biopharmaceutical company specializing in
precision medicine for the treatment of resistant and metastatic
cancers, today announced that a scientific abstract on its leading
drug candidate, OPM-101, has been presented at the United European
Gastroenterology (UEG) Week congress, October 12-15, 2024, in
Vienna, Austria.
"I am thrilled to have had the opportunity to present for the
first time the results of the Phase 1 clinical trial with OPM-101
in healthy volunteers at UEG Week" said Professor Laurent
Peyrin-Biroulet, MD, PhD, Professor of Gastroenterology at CHRU of
Nancy. "This presentation provides strong evidence that OPM has
the potential to advance the treatment of Chronic Inflammatory
Bowel Disease as a daily oral therapy for people living with
ulcerative colitis."
Poster: MP119
Title: Unveiling the strong safety profile and high
target engagement of OPM-101, a first-in-class orally available
RIPK2 inhibitor, in a phase 1 clinical trial in healthy
volunteers
Presenter: Laurent Peyrin-Biroulet, Professor of
Gastroenterology at CHRU of Nancy and an internationally recognized
expert in IBD. He is the Director of the IHU INFINY, an Institute
dedicated to the prevention and cure of IBD.
Session: Novel therapeutic approaches in IBD
Time and date: 13 October 2024, 3:30-4:30pm CEST
For more information on OPM's clinical program and company
updates, please visit the company's website
(https://www.oncodesign.com/fr/). The conference program is
available on the UEG website.
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), founded in 2022, is a
biopharmaceutical company specializing in precision medicine,
dedicated to the discovery of treatments for resistant and
metastatic cancers.
OPM currently has two kinase inhibitors in clinical trials:
OPM-101, for the treatment of chronic immuno-inflammatory digestive
diseases, demonstrated high target engagement and absence of
toxicity in its phase I trial in healthy volunteers. Phase Ib/IIa
is scheduled to start at the end of 2024. OPM-201, licensed to
Servier for the treatment of Parkinson's disease, completed its
Phase I trial in healthy volunteers this year, with Phase II
scheduled to start in 2025. OPM-102, a follower of OPM-101, is in
preclinical development.
Finally, a third kinase inhibitor, OPM-102, targeting oncology,
is in preclinical development.
These three molecules come from the Nanocyclix® technology
platform, which enables the design and selection of small
macrocyclic kinase inhibitors that are highly effective and
selective. We now have 12,000 such molecules in our library and
will be using AI to accelerate the discovery of drug candidates
while reducing the cost of this phase.
OPM's two other technology platforms are:
(i) OncoSNIPER, for the selection of therapeutic targets using
artificial intelligence, in partnership with Servier for the search
of targets in pancreatic cancer,
(ii) PROMETHE® for the design and selection of radiolabeled
biological molecules for systemic radiotherapy, for which we have
signed a partnership agreement with Navigo and are currently
discussing partnerships with other vectorization companies.
OPM, co-founded by Philippe Genne, Jan Hoflack and Karine
Lignel, is based in Dijon, in the heart of the university and
hospital cluster, and has 19 employees.
Further information: oncodesign.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241014952808/en/
OPM Karine Lignel Deputy General Manager Tel: +33 (0)3 80
78 41 93 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel: +33 (0)1 44 71
00 15 oncodesign@newcap.eu
Oncodesign Precision Med... (EU:ALOPM)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Oncodesign Precision Med... (EU:ALOPM)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
